兴业证券指出，创新药板块景气度可持续，"创新+国际化"创新药产业趋势不变，始终是医药板块的核 心方向。创新药产业预计将持续获得政策支持，中国创新药的全球竞争力持续增强，商业化盈利持续兑 现。同时，可关注基本面开始改善的创新药产业链，海外业务方面订单和业绩已开始恢复，国内业务具 备自主可控逻辑，上游业绩已出现复苏趋势。国内方面，2025年需求有望迎来复苏，若经济基本面预期 转好，消费医疗领域（医疗服务、中药OTC与连锁药店等）基本面有望实现回升。同时，医疗器械2025 年亦有望迎来改善。 机构继续坚定看优质创新&创新产业链，大产业趋势面前，无惧短期扰动，自身够硬的情况下，外来的 任何扰动调整就是买入机会。美国降息预期提升，将强化全球流动性与科技股的趋势，对于踏空医药上 半场行情的投资者，可以借道医疗创新ETF(516820)布局医药核心资产反弹行情。 9月25日早盘，医疗创新ETF(516820.SH) 强势上涨0.98%，，成分股百利天恒(688506)上涨3.87%，恒瑞 医药(600276)上涨3.38%，新产业(300832)上涨2.87%，药明康德(603259)，三生国健(688336)等个股跟 涨 ...

Group 1 - The overnight SPDR S&P Biotech ETF (XBI) rose by 3.1%, while the Hong Kong pharmaceutical sector (159718.SZ) opened high but continued to weaken, currently down by 0.93% [1] - Among the constituent stocks, Haijia Medical (06078) led the gains with an increase of 7.41%, while Innovent Biologics (01801) saw the largest decline at 6.57% [1] - Industrial insights suggest that the innovative drug sector's prosperity is sustainable, with a focus on "innovation + internationalization" as the core direction of the pharmaceutical sector [1] Group 2 - The innovative drug industry is expected to continue receiving policy support, enhancing the global competitiveness of Chinese innovative drugs and realizing commercial profitability [1] - There is an improvement in the fundamentals of the innovative drug supply chain, with overseas orders and performance beginning to recover, and domestic business showing a self-controllable logic [1] - The demand in the domestic market is anticipated to recover by 2025, with potential improvements in the consumption medical field and medical devices [1] Group 3 - Institutions remain confident in high-quality innovation and the innovative industry chain, viewing any external disturbances as buying opportunities [2] - The Hong Kong pharmaceutical ETF is well-balanced, including innovative drugs, CXO, internet healthcare, and innovative devices, serving as a convenient standardized tool for investors [2] - Recommendations are made to pay attention to the Hong Kong pharmaceutical ETF (159718.SZ) and its connected funds (Class A: 019598, Class C: 019599) [2]

Group 1 - The National Medical Products Administration of China approved 210 innovative drugs during the "14th Five-Year Plan" period, indicating a sustained growth trend in the sector [1] - In the first seven months of this year, 50 innovative drugs were approved, surpassing the total of 48 approved in the entire previous year [1] - The current landscape of China's innovative drugs has transitioned from quantitative to qualitative changes, with leading trends in new targets, technologies, and diseases [1] Group 2 - Chinese innovative drug assets are experiencing a wave of international expansion, with significant recognition of their value globally [2] - The upfront payments and total transaction values for Chinese innovative drug assets have rapidly increased from $8.7 billion and $99.4 billion in 2020 to $49.4 billion and $561.2 billion in 2024 [2] - In the first half of 2025, the total transaction value reached $635.5 billion, exceeding the total for 2024 and accounting for approximately 40% of the global license-out transaction total [2]

Core Viewpoint - The Hong Kong stock market for innovative drugs continues to rise, with the Hong Kong Stock Connect Innovative Drug ETF (520880) increasing by 3.24%, marking three consecutive days of gains [1]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) has shown a remarkable year-to-date increase of 115.29%, leading the performance among various innovative drug indices [3]. - Major innovative drug companies such as BeiGene and Innovent Biologics have seen significant stock price increases, with BeiGene rising nearly 5% and Innovent Biologics over 3% [4]. Group 2: Policy and Industry Trends - On August 28, the National Healthcare Security Administration announced the preliminary review of the 2025 medical insurance and commercial insurance innovative drug directory, which includes new drugs and notable CAR-T products [2]. - The innovative drug sector is transitioning from capital-driven growth to profit-driven growth, with a positive trend in profitability across the industry [6]. Group 3: Index Adjustments - The Hang Seng Index has announced a revision to the Hang Seng Stock Connect Innovative Drug Select Index, removing companies primarily engaged in CXO services to focus on innovative drug research and development firms [8][9]. - This adjustment is expected to enhance the index's performance by eliminating disturbances from CXO companies, reflecting the maturation of China's innovative drug development [9].

Group 1 - Long-term funds such as social security and basic pension insurance funds have significantly increased their holdings in over 100 A-shares, with more than 40 social security fund portfolios and over 20 pension fund portfolios entering the top ten shareholders of approximately 160 listed companies by the end of Q2 [1] - Notable stocks favored by social security funds include Nanwei Medical, Kaili New Materials, and Su Shi Testing, while pension funds have shown interest in Chunfeng Power and Lvxiao Technology [1] Group 2 - The 27th Asia Pet Expo showcased a rapid development in the "pet economy," with over 2,600 exhibitors and an expected attendance of over 510,000 visitors, highlighting the importance of smart technology in this market [2] - The event featured innovations such as smart collars enabling remote communication between pets and their owners, indicating a shift towards intelligent solutions in pet care [2] Group 3 - Innovative pharmaceutical companies like Heng Rui Medicine reported strong performance in H1 2025, with revenue of 15.761 billion yuan, a 15.88% increase, and a net profit of 4.450 billion yuan, up 29.67% [3] - The sector is transitioning from "follower" to "leader," with a focus on innovation and internationalization, indicating a sustained positive outlook for the innovative drug sector [3] Group 4 - Major engineering projects under the "14th Five-Year Plan" are progressing rapidly, with increased investment expected in new infrastructure and key technologies, including 5G/6G and advanced manufacturing [4] Group 5 - Foreign capital is increasingly optimistic about the Chinese market, with significant inflows into A-shares, driven by improved corporate earnings and macroeconomic conditions [5] - The influx of various investors, including hedge funds and individual investors, reflects a positive sentiment towards China's economic recovery [5] Group 6 - Kuaishou and Bilibili reported record high revenues for Q2 2025, with Kuaishou achieving 35 billion yuan in revenue, a 13.1% year-on-year increase, and Bilibili reaching 7.34 billion yuan, up 20% [6][7] - Both companies attribute their growth to diversified business strategies and increased user engagement [6][7] Group 7 - The eVTOL (electric vertical takeoff and landing) market is witnessing a surge in demand for GWh-level batteries, with several battery manufacturers collaborating with eVTOL companies to address key challenges [8] - Solid-state batteries are highlighted as a potential core choice for eVTOL manufacturers due to their high energy density and safety, although challenges remain in commercialization [8] Group 8 - The exoskeleton robot industry is on the verge of a breakthrough, driven by advancements in AI, flexible drives, and lightweight materials, alongside increasing demand from an aging population and outdoor economy [9] - The integration of exoskeleton technology into tourism and daily life is expected to accelerate its commercialization [9] Group 9 - Over 20 titanium dioxide producers have announced price increases, with Longbai Group raising prices by 500 yuan per ton domestically and 70 USD per ton internationally, indicating a trend across the industry [10] Group 10 - The automotive parts industry is experiencing positive mid-year performance, with over 60% of 47 listed companies reporting year-on-year profit growth, driven by sustained demand for new energy vehicles and steady export growth [16]

Core Insights - Heng Rui Medicine reported a revenue of 15.76 billion yuan for the first half of 2025, marking a year-on-year growth of 15.88% [1] - The net profit attributable to shareholders reached 4.45 billion yuan, up 29.67% year-on-year [1] - The operating cash flow net amount was 4.3 billion yuan, reflecting a 41.80% increase compared to the previous year [1] - The company’s innovative drug sales and licensing revenue accounted for 60.66% of total revenue, with innovative drug sales reaching 7.57 billion yuan [1][2] Company Performance - Heng Rui Medicine's innovative drugs such as Rivoceranib, Darsylin, and Henggrelin continued to see rapid revenue growth [2] - The company received significant licensing fees, including 200 million USD from Merck Sharp & Dohme and 75 million USD from IDEAYA, contributing to revenue growth [2] - The company invested over 3.87 billion yuan in R&D during the first half of 2025, with 3.23 billion yuan classified as expense-based R&D [2] - Heng Rui has over 100 innovative products in clinical development and 400 clinical trials ongoing domestically and internationally [2] Industry Trends - The innovative drug sector in China is transitioning from "follower" to "leader," with a sustained increase in market vitality [1][5] - Other companies like BeiGene and Hansoh Pharmaceutical also reported significant revenue growth, with BeiGene achieving a 46% increase in total revenue [3] - The innovative drug market in China is expected to exceed 2 trillion yuan by 2030, representing a 264% growth compared to 2024 [5] - The industry is witnessing a shift towards internationalization and innovation as key growth drivers [3][4]

Group 1 - The Hong Kong stock market showed mixed performance on August 12, with the Hang Seng Index rising by 0.09% and hovering around the 25,000-point mark, while the Hang Seng Tech Index fell by 0.39% [1] - The pharmaceutical and biotech industry is transitioning into the "Innovation Drug 3.0" era, with expectations for significant growth in overseas markets by 2025, where numerous products are projected to exceed peak sales of $3-5 billion [1] - The medical device industry is expected to improve by 2025, experiencing a similar acceleration in innovation and internationalization as seen in pharmaceuticals, with a potential recovery in hospital equipment procurement [1] Group 2 - The trend of "innovation + internationalization" in the pharmaceutical sector is clear, supported by ongoing policies that enhance global competitiveness and gradually realize commercial profitability [1] - The normalization of centralized procurement is leading to a transformation in the medical device sector, with expectations for a stable development trajectory as uncertainties diminish [1] - If the procurement rules for consumables and IVD are moderate, domestic manufacturers may drive valuation recovery by exchanging price for volume [1]

Group 1 - The core viewpoint of the article highlights that the pharmaceutical and biotechnology industry is transitioning into the Innovation Drug 3.0 era, moving from "followers" to "leaders," with 2025 expected to be a pivotal year for China's innovative drugs in overseas markets, featuring numerous products with peak expectations exceeding $3-5 billion [1] - The article emphasizes the sustainable prosperity of the innovative drug sector, driven by a clear trend of "innovation + internationalization," supported by continuous policy backing, enhancing global competitiveness, and gradual realization of commercial profitability [1] - The medical device industry is anticipated to improve by 2025, undergoing a similar acceleration in innovation and internationalization as seen in pharmaceuticals, with a recovery in hospital equipment procurement expected, contingent on moderate procurement rules for consumables and IVD [1] Group 2 - The article mentions that the Guotai ChiNext Pharmaceutical ETF (159377) tracks the Innovation Pharmaceutical Index (399275), which can experience daily fluctuations of up to 20%, focusing on innovative biopharmaceuticals and related medical services [1] - The Innovation Pharmaceutical Index selects listed companies involved in innovative drug research and development, biotechnology, and related medical services, reflecting the overall performance of the innovative pharmaceutical sector, with a focus on high growth and innovation capabilities [1]

Group 1: ETF Performance - The liquidity of the Kexin Pharmaceutical ETF managed by Jiashi has a turnover rate of 24.54%, with a trading volume of 59.44 million yuan, indicating active market trading [2] - As of August 11, the Kexin Pharmaceutical ETF managed by Jiashi has reached a recent high in scale of 243 million yuan, ranking first among comparable funds [2] - The latest share count for the Kexin Pharmaceutical ETF managed by Jiashi is 205 million shares, also a recent high, and ranks first among comparable funds [2] Group 2: Fund Inflows and Returns - The Kexin Pharmaceutical ETF managed by Jiashi has seen a net inflow of 2.94 million yuan recently, with 4 out of the last 5 trading days showing net inflows totaling 20.52 million yuan [2] - As of August 11, the Kexin Pharmaceutical ETF managed by Jiashi has achieved a net value increase of 52.43% over the past year, ranking 584 out of 2954 in the index stock fund category, placing it in the top 19.77% [2] - Since its inception, the Kexin Pharmaceutical ETF managed by Jiashi has recorded a highest monthly return of 23.29%, with the longest consecutive monthly gains being 6 months and a maximum cumulative increase of 41.76% [2] Group 3: Top Holdings and Market Trends - As of July 31, the top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for a total of 49.14%, with leading companies including United Imaging Healthcare and BeiGene [2] - The innovative drug sector has maintained rapid growth in product revenue and external licensing over the past three years, with significant BD transactions this year driving the overall market trend [4] - The innovative drug sector is expected to sustain its growth due to ongoing policy support and increasing global competitiveness, while the medical device industry is anticipated to improve by 2025 [5]

兴业证券研报称，创新药板块景气度可持续，"创新+国际化"的创新药产业趋势不变，始终是医药板块 的核心方向，政策预计持续支持产业，全球竞争力预计持续加强，商业化盈利预计持续兑现。 今日，恒生港股通创新药指数新编制方案正式生效，明确剔除CXO企业，聚焦创新药企，成为ETF跟踪 指数中首批"纯度"100%的创新药指数。回测显示，此次调整后，该指数自2023年7月10日指数发布以来 年化收益率超47%，夏普比率也更高。恒生创新药ETF（159316）是目前唯一跟踪该指数的产品，可助 力投资者精准捕捉行业发展趋势。 港股创新药板块早盘震荡调整，截至10:28，恒生港股通创新药指数下跌2.4%，资金逆势"抢筹"，恒生 创新药ETF（159316）盘中获净申购1000万份。Wind数据显示，截至上周五，该产品近一月净流入超5 亿元，产品规模实现翻倍。 ...